ATE258430T1 - Zubereitung mit verzögerter wirkstoffabgabe für aii antagonisten, ihre herstellung und verwendung - Google Patents

Zubereitung mit verzögerter wirkstoffabgabe für aii antagonisten, ihre herstellung und verwendung

Info

Publication number
ATE258430T1
ATE258430T1 AT99907846T AT99907846T ATE258430T1 AT E258430 T1 ATE258430 T1 AT E258430T1 AT 99907846 T AT99907846 T AT 99907846T AT 99907846 T AT99907846 T AT 99907846T AT E258430 T1 ATE258430 T1 AT E258430T1
Authority
AT
Austria
Prior art keywords
preparation
production
delayed release
aii antagonists
angiotensin
Prior art date
Application number
AT99907846T
Other languages
English (en)
Inventor
Yasutaka Igari
Akira Saikawa
Yoshiyuki Inada
Shigeru Kamei
Original Assignee
Takeda Chemical Industries Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Chemical Industries Ltd filed Critical Takeda Chemical Industries Ltd
Application granted granted Critical
Publication of ATE258430T1 publication Critical patent/ATE258430T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1611—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
AT99907846T 1998-03-04 1999-03-03 Zubereitung mit verzögerter wirkstoffabgabe für aii antagonisten, ihre herstellung und verwendung ATE258430T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP5236698 1998-03-04
PCT/JP1999/001011 WO1999044590A1 (en) 1998-03-04 1999-03-03 Sustained-release preparation for aii antagonist, production and use thereof

Publications (1)

Publication Number Publication Date
ATE258430T1 true ATE258430T1 (de) 2004-02-15

Family

ID=12912818

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99907846T ATE258430T1 (de) 1998-03-04 1999-03-03 Zubereitung mit verzögerter wirkstoffabgabe für aii antagonisten, ihre herstellung und verwendung

Country Status (21)

Country Link
US (2) US6589547B1 (de)
EP (1) EP1058541B1 (de)
KR (1) KR20010086245A (de)
CN (1) CN1291888A (de)
AT (1) ATE258430T1 (de)
AU (1) AU2745199A (de)
BR (1) BR9908474A (de)
CA (1) CA2318446C (de)
DE (1) DE69914460T2 (de)
EE (1) EE200000499A (de)
ES (1) ES2214013T3 (de)
HU (1) HUP0101439A3 (de)
ID (1) ID25640A (de)
IL (1) IL137979A0 (de)
LT (1) LT4800B (de)
LV (1) LV12585B (de)
NO (1) NO20004350L (de)
PL (1) PL342684A1 (de)
SK (1) SK11902000A3 (de)
WO (1) WO1999044590A1 (de)
ZA (1) ZA991706B (de)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1291888A (zh) * 1998-03-04 2001-04-18 武田药品工业株式会社 Aⅱ拮抗剂的缓释制剂、其制备和用途
DK1197223T3 (da) 1999-04-28 2005-05-30 Takeda Pharmaceutical Farmaceutisk præparat til forebyggelse, behandling eller udviklingsinhibition af simpel retinopati eller præproliferativ retinopati
SE9903028D0 (sv) * 1999-08-27 1999-08-27 Astra Ab New use
WO2001060362A1 (en) * 2000-02-18 2001-08-23 Takeda Chemical Industries, Ltd. TNF-α INHIBITORS
CA2400845A1 (en) * 2000-02-21 2001-08-23 Takeda Chemical Industries, Ltd. Sustained-release preparation of physiologically active compound slightly soluble in water and production process and use of the same
US20030187038A1 (en) * 2000-08-25 2003-10-02 Yoshimi Imura Fibrinogen-lowering agents
EP1329218A4 (de) * 2000-10-25 2007-04-04 Takeda Pharmaceutical Wirkstoffe zur vorbeugung und behandlung portaler hypertonie
EP1369130A1 (de) * 2001-03-16 2003-12-10 Takeda Chemical Industries, Ltd. Verfahren zur herstellung eines präparats mit verzögerter freisetzung
US20040219208A1 (en) * 2001-08-03 2004-11-04 Ryu Kawamura Sustained-release medicines
BRPI0105509B8 (pt) * 2001-11-05 2021-05-25 Univ Minas Gerais formulações do peptídeo angiotensina-(1-7) usando as ciclodextrinas, lipossomas e o polímero plga
WO2003041739A1 (en) 2001-11-13 2003-05-22 Takeda Chemical Industries, Ltd. Anticaner agents
AU2002349673A1 (en) * 2001-12-03 2003-06-17 Takeda Chemical Industries, Ltd. Insulin resistance improving agents
US7700074B2 (en) * 2002-02-07 2010-04-20 Pettegrew Jay W Method and system for diagnosis of neuropsychiatric disorders including chronic alcoholism
US7407778B2 (en) * 2002-02-07 2008-08-05 Pettegrew Jay W Compounds, compositions and methods for treating neuropsychiatric disorders
ATE551056T1 (de) * 2002-12-27 2012-04-15 Takeda Pharmaceutical Mittel zur hemmung der körpergewichtszunahme
US20050038093A1 (en) * 2003-05-02 2005-02-17 Boehringer Ingelheim International Gmbh Treating diabetic retinopathy with angiotensin II receptor blockers
US20060257842A1 (en) * 2003-05-29 2006-11-16 Pettegrew Jay W Cryopreservation media and molecules
US7815894B2 (en) * 2003-05-29 2010-10-19 Jay W. Pettegrew Compounds, compositions and methods for medical imaging of neuropsychiatric disorders
WO2005097109A1 (en) * 2004-04-01 2005-10-20 Daniel Batlle Methods for achieving a protective ace2 expression level
EP1750862B1 (de) 2004-06-04 2011-01-05 Teva Pharmaceutical Industries Ltd. Irbesartan enthaltende pharmazeutische zusammensetzung
CA2583768A1 (en) * 2004-10-07 2006-04-13 Takeda Pharmaceutical Company Limited Agent for prophylaxis or treatment of metabolic syndrome
US8022086B2 (en) * 2004-10-29 2011-09-20 Kowa Co., Ltd. Therapeutic agent for glomerular disease
EP1850835A1 (de) * 2005-02-21 2007-11-07 Flamel Technologies Orale pharmazeutische form von losartan
GEP20115138B (en) * 2005-03-30 2011-01-10 Takeda Pharmaceuticals Co Benzimidazole derivative and use as angiotensin ii antagonist
WO2007032019A2 (en) * 2005-08-22 2007-03-22 Alembic Limited Process for preparing valsartan
MX2009001429A (es) * 2006-08-10 2009-02-17 Takeda Pharmaceutical Composicion farmaceutica.
EP1897537A1 (de) * 2006-09-04 2008-03-12 Novartis AG Zusammensetzung enthaltend einen Angiotensin II antagonisten
PE20081364A1 (es) * 2006-09-04 2008-12-04 Novartis Ag Composicion farmaceutica que comprende valsartan
EP1908469A1 (de) 2006-10-06 2008-04-09 Boehringer Ingelheim Vetmedica Gmbh Angiotensin II Rezeptor Antagonisten zur Behandlung von systemischen Krankheiten bei Katzen
WO2008075762A1 (en) 2006-12-18 2008-06-26 Takeda Pharmaceutical Company Limited Sustained-release composition and method for producing the same
CN101011393B (zh) * 2007-02-16 2010-10-06 广州柏赛罗药业有限公司 厄贝沙坦胃内滞留型缓释药物组合物
WO2008123536A1 (en) * 2007-03-28 2008-10-16 Takeda Pharmaceutical Company Limited Solid pharmaceutical composition comprising a benzimidazole-7-carboxylate derivative and a ph control agent
KR101209319B1 (ko) * 2008-04-29 2012-12-06 한올바이오파마주식회사 안지오텐신-ⅱ-수용체 차단제를 포함하는 약제학적 제제
CA2761576C (en) 2009-05-20 2017-08-22 Boehringer Ingelheim Vetmedica Gmbh Oral suspension comprising telmisartan
WO2018002673A1 (en) 2016-07-01 2018-01-04 N4 Pharma Uk Limited Novel formulations of angiotensin ii receptor antagonists

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2751907A (en) * 1953-09-18 1956-06-26 Bishop & Co Platinum Works J Pellet injector
JPS5671074A (en) 1979-11-12 1981-06-13 Takeda Chem Ind Ltd 1,2-disubstituted-4-halogenoimidazole-5-acetic acid derivative
JPS5671073A (en) 1979-11-12 1981-06-13 Takeda Chem Ind Ltd Imidazole derivative
IE802177L (en) 1980-10-21 1981-05-12 Takeda Chemical Industries Ltd Imidazol-5-ylacetic acid derivatives
JPS58157768A (ja) 1982-03-16 1983-09-19 Takeda Chem Ind Ltd ４−クロロ−２−フエニルイミダゾ−ル−５−酢酸誘導体
CA1334092C (en) 1986-07-11 1995-01-24 David John Carini Angiotensin ii receptor blocking imidazoles
US4820843A (en) 1987-05-22 1989-04-11 E. I. Du Pont De Nemours And Company Tetrazole intermediates to antihypertensive compounds
US4880804A (en) 1988-01-07 1989-11-14 E. I. Du Pont De Nemours And Company Angiotensin II receptor blocking benzimidazoles
US5015651A (en) 1988-01-07 1991-05-14 E. I. Du Pont De Nemours And Company Treatment of hypertension with 1,2,4-angiotensin II antagonists
CA1338238C (en) 1988-01-07 1996-04-09 David John Carini Angiotensin ii receptor blocking imidazoles and combinations thereof with diuretics and nsaids
US4898732A (en) * 1988-05-04 1990-02-06 The Clinipad Corporation Inhibiting of tumor growth with an antagonist of the renin-angioten-sin system
DE3928177A1 (de) 1989-04-08 1991-02-28 Thomae Gmbh Dr K Benzimidazole, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung
IE64514B1 (en) 1989-05-23 1995-08-09 Zeneca Ltd Azaindenes
ATE107517T1 (de) * 1989-05-25 1994-07-15 Takeda Chemical Industries Ltd Transdermales therapeutisches mittel.
EP0403158A3 (de) 1989-06-14 1991-12-18 Smithkline Beecham Corporation Imidazolyl-Alkensäuren
DK0479903T3 (da) 1989-06-30 1996-03-18 Du Pont Substituerede imidazoler og deres anvendelse som angiotensin II hæmmere
CA2020073A1 (en) 1989-07-03 1991-01-04 Eric E. Allen Substituted quinazolinones as angiotensin ii antagonists
EP0407342A3 (en) 1989-07-06 1991-07-10 Ciba-Geigy Ag Pyrimidine derivatives
EP0409332A3 (en) 1989-07-19 1991-08-07 Merck & Co. Inc. Substituted triazoles as angiotensin ii antagonists
US5225205A (en) * 1989-07-28 1993-07-06 Debiopharm S.A. Pharmaceutical composition in the form of microparticles
ATE113281T1 (de) 1989-08-02 1994-11-15 Takeda Chemical Industries Ltd Pyrazol-derivate, verfahren zu deren herstellung und anwendung.
IL95975A (en) 1989-10-24 1997-06-10 Takeda Chemical Industries Ltd N-benzyl- 2-alkylbenzimidazole derivatives, their production and pharmaceutical compositions containing them
EP0434038A1 (de) 1989-12-22 1991-06-26 Takeda Chemical Industries, Ltd. Kondensierte Imidazolderivate, ihre Herstellung und Verwendung
ATE169915T1 (de) 1990-02-15 1998-09-15 Takeda Chemical Industries Ltd Pyrimidindionderivate, deren herstellung und verwendung
CA2036618C (en) * 1990-02-22 2002-10-29 Akira Morimoto Fused thiophene derivatives, their production and use
IL99246A0 (en) * 1990-09-10 1992-07-15 Abbott Lab Angiotensin ii receptor antagonists and pharmaceutical compositions containing them
US5171217A (en) * 1991-02-28 1992-12-15 Indiana University Foundation Method for delivery of smooth muscle cell inhibitors
TW274551B (de) 1991-04-16 1996-04-21 Takeda Pharm Industry Co Ltd
AU2494792A (en) * 1991-08-19 1993-03-16 E.I. Du Pont De Nemours And Company Angiotensin ii receptor blocking imidazolinone derivatives
TW284688B (de) * 1991-11-20 1996-09-01 Takeda Pharm Industry Co Ltd
US5656297A (en) 1992-03-12 1997-08-12 Alkermes Controlled Therapeutics, Incorporated Modulated release from biocompatible polymers
GB2272899A (en) * 1992-11-30 1994-06-01 Du Pont Merck Pharma Angiotensin-11 receptor blocking cycloalkylbenzylimidazoles
ATE204276T1 (de) 1992-12-22 2001-09-15 Takeda Chemical Industries Ltd Heterocyclische verbindungen mit angiotensin-ii- antagonistischer wirkung und ihre anwendung
US5288720A (en) * 1993-04-23 1994-02-22 American Cyanamid Company Angiotensin II receptor blocking 2,3,6 substituted quinazolinones
US5721263A (en) * 1993-06-07 1998-02-24 Takeda Chemical Industries, Ltd. Pharmaceutical composition for angiotensin II-mediated diseases
DK0797988T3 (da) * 1993-07-19 2009-05-11 Univ British Columbia Anti-angiogene præparater og fremgangsmåder til anvendelse deraf
JPH0789849A (ja) 1993-09-20 1995-04-04 Fujisawa Pharmaceut Co Ltd 徐放性製剤
AU6242096A (en) * 1995-06-27 1997-01-30 Takeda Chemical Industries Ltd. Method of producing sustained-release preparation
JP4316013B2 (ja) 1996-03-29 2009-08-19 スミスクライン・ビーチャム・コーポレイション エプロサルタン二水和物ならびにその製法および処方
GB9613470D0 (en) * 1996-06-27 1996-08-28 Ciba Geigy Ag Small solid oral dosage form
US6201002B1 (en) * 1997-01-10 2001-03-13 Merck & Co., Inc. Method for reducing mortality with an angiotensin II antagonist
US5958884A (en) * 1997-04-11 1999-09-28 The Brigham And Women's Hospital, Inc. Compositions and methods for treating erectile dysfunction
US6306826B1 (en) * 1997-06-04 2001-10-23 The Regents Of The University Of California Treatment of heart failure with growth hormone
DE19741635A1 (de) * 1997-09-22 1999-03-25 Hoechst Marion Roussel De Gmbh Biphenylsulfonylcyanamide, Verfahren zu ihrer Herstellung und ihre Verwendung als Medikament
CN1291888A (zh) * 1998-03-04 2001-04-18 武田药品工业株式会社 Aⅱ拮抗剂的缓释制剂、其制备和用途

Also Published As

Publication number Publication date
BR9908474A (pt) 2000-12-05
ID25640A (id) 2000-10-19
PL342684A1 (en) 2001-07-02
WO1999044590A1 (en) 1999-09-10
SK11902000A3 (sk) 2001-02-12
KR20010086245A (ko) 2001-09-10
HUP0101439A3 (en) 2002-09-30
LT4800B (lt) 2001-06-25
EE200000499A (et) 2002-02-15
EP1058541A1 (de) 2000-12-13
LT2000082A (en) 2001-03-26
DE69914460T2 (de) 2004-10-28
AU2745199A (en) 1999-09-20
EP1058541B1 (de) 2004-01-28
IL137979A0 (en) 2001-10-31
ZA991706B (en) 2000-10-03
US7294344B2 (en) 2007-11-13
HUP0101439A2 (hu) 2001-10-28
LV12585B (en) 2001-03-20
US6589547B1 (en) 2003-07-08
CA2318446A1 (en) 1999-09-10
ES2214013T3 (es) 2004-09-01
CN1291888A (zh) 2001-04-18
US20030198676A1 (en) 2003-10-23
NO20004350D0 (no) 2000-09-01
LV12585A (en) 2000-12-20
CA2318446C (en) 2008-09-23
NO20004350L (no) 2000-10-03
DE69914460D1 (de) 2004-03-04

Similar Documents

Publication Publication Date Title
ATE258430T1 (de) Zubereitung mit verzögerter wirkstoffabgabe für aii antagonisten, ihre herstellung und verwendung
DE69926806D1 (de) N-ureidoalkylpiperidine als modulatoren der aktivität der chemokinrezeptoren
DE69926919D1 (de) N-ureidoalkylpiperidine als modulatoren der aktivität der chemokinrezeptoren
BR0014651A (pt) Inibidores de adesão de célula mediada por "alfa" l beta2
DK1131315T3 (da) Polyhydroxylerede heterocykliske derivater som antikoagulanter
ATE425139T1 (de) Benzamidinderivate
EA200100058A1 (ru) 4-бензилпиперидиналкилсульфоксидные гетероциклические соединения и их применение в качестве подтип-избирательных антагонистов nmda-рецепторов
PT863875E (pt) Novos compostos 4-(oxialcoxifenil)-3-oxi-piperidina para o tratamento de insuficiencia cardiaca e renal
EP0795548A4 (de) Chinazozin derivate und deren verwendung
DE69841307D1 (de) Verwendung von peroxiden zur bekämpfung der haarigen warzenerkrankung
ATE272398T1 (de) Verwendung von ep4 rezeptorliganden zur behandlung von neuropathischen schmerz
DE60100625D1 (de) Verwndung von verbindungen mit 5-ht1a aktivität zur behandlung von krankheiten der äusseren retina
DE69637964D1 (de) Derivaten von Nodulisporen Säure
BR9804027A (pt) Novos beta-ceto ésteres
EA200200742A1 (ru) 1,2-диарилбензимидазолы для лечения заболеваний, связанных с активацией микроглии
EA200301143A1 (ru) Производные гетероциклилалкокси-, алкилтио- и -алкиламинобензазола в качестве лигандов 5-гидрокситриптамина-6
DE69841267D1 (de) Verwendung von r-carprofen zur Vorbeugung der Alzheimerschen Krankheit
DE60028928D1 (de) Verwendung von angiotensin ii rezeptorantagonisten zur behandlung von akutem myokardischen infarkt
DK0750616T3 (da) Syreadditionssalte af 2,3,4,5-tetrahydro-1H-3-benzazapinforbindelser
TR199800165T1 (xx) (R)-5-bromo-n-(1-etil-4-metil hekzahidro-1h-1,4-diazepin-6-il)-2-metoksi-6- metilamino-3-piridinkarboksamid, bunu haz�rlamaya mahsus y�ntem ve bu bile�i�i ihtiva eden farmas�tik terkip.
ATE360423T1 (de) Verwendung von chymase hemmern gegen vaskuläre lipidablagerung
RS51316B (sr) Nova upotreba (r)-(-)-2-/5-(4-fluorofenil)-3- piridilmetilaminometil/-hromana i njegovih fiziološki prihvatljivih soli
TR200001080T2 (tr) 2 ile ikame edilmiş 1,2-Benisotiyazol türevleri ve bunların serrotonın antagonistleri
FR2740337B1 (fr) Compositions pharmaceutiques stabilisees contenant un derive ayant une activite adrenergique
DK1148129T3 (da) Modifikation af betacellulin

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1058541

Country of ref document: EP

REN Ceased due to non-payment of the annual fee